Adalimumab

From WikiMD.org
Jump to navigation Jump to search

Adalimumab (pronounced as a-dal-i-mu-mab) is a biopharmaceutical drug used primarily to treat autoimmune diseases. It is a monoclonal antibody that works by blocking tumor necrosis factor alpha (TNF-alpha), a substance in the body that causes inflammation.

Etymology

The name "Adalimumab" is derived from the parts: "ada-" from human, "-lim-" from immunoglobulin (Ig), "-u-" from human, and "-mab" meaning monoclonal antibody.

Usage

Adalimumab is used to treat various autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is also used in the treatment of juvenile idiopathic arthritis in children.

Mechanism of Action

Adalimumab binds specifically to tumor necrosis factor alpha (TNF-alpha) and blocks its interaction with the p55 and p75 cell surface TNF receptors. This results in the reduction of the inflammatory response which is a characteristic of autoimmune diseases.

Side Effects

Common side effects of Adalimumab include infection, injection site reactions, headache, and rash. Serious side effects may include tuberculosis, sepsis, and other infections, lymphoma, and autoimmune disorders.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski